<DOC>
	<DOCNO>NCT01489033</DOCNO>
	<brief_summary>Based EMA ( European Medicines Agency ) new guideline clinical development product immunotherapy treatment allergic disease aim study assess safety tolerability three different subcutaneous immunotherapy dose escalation patient allergic pollen Phleum pratense .</brief_summary>
	<brief_title>Subcutaneous Immunotherapy Patients Sensitized Phleum Pratense</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients must sign informed consent form . 2 . Patients must 18 60 year age . 3 . Patients obtain prick test result great equal 3 mm diameter specific IgE great equal class 2 ( CAP/PHADIA ) Phleum pratense . 4 . Patients seasonal allergic rhinoconjunctivitis Phleum pratense minimum 2 year prior study participation . Although allergic rhinoconjunctivitis pathology study , inclusion patient mild moderate concomitant asthma allow . 5 . Patients preferably monosensitized Phleum pratense . Polysensitized patient seasonal allergen accept sensitization cause Pollens whose season overlap Phleum pratense . Polysensitized patient perennial allergen also accept clinically relevant study period . 6 . Women childbearing potential must negative urine pregnancy test Screening visit/Visit 0 7 . Women childbearing potential must agree use appropriate contraception method study sexually active . 1 . Stable continued use medication allergic pathology 2 week prior inclusion . 2 . Patients sensitise overlap seasonal allergen specific IgE level great equal class 2 CAP/PHADIA . 3 . Patients receive immunotherapy previous 5 year Phleum pratense allergen cross reactivity patient currently receive immunotherapy allergen . 4 . Patients severe asthma FEV1 low 60 % asthma require inhale systemic corticoid treatment time study entry within 8 week prior treatment commencement . 5 . Patients : immunological , cardiac , renal hepatic illness medical condition investigator deem relevant interfere study . 6 . Patients previous history anaphylaxis 7 . Patients unstable angina 8 . Patients uncontrolled hypertension 9 . Patients clinically significant arrythmias 10 . Patients neoplasia 11 . Patients clinically relevant malformation upper respiratory tract . 12 . Other chronic immunological disease could interfere assessment investigation product could generate additional risk patient 13 . Patients participate another clinical trial within 3 month prior enrolment . 14 . Patients treatment tricyclic antidepressives , psychotropics betablockers 15 . Female patient pregnant breastfeed woman childbearing potential agree use appropriate contraception method study sexually active , surgical sterilise present incapacity bear 16 . Patient attend visit 17 . Patient 's lack collaboration refusal participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Phleum pratense</keyword>
	<keyword>Timothy grass pollen allergy</keyword>
	<keyword>subcutaneous immunotherapy</keyword>
</DOC>